Peptide Encyclopedia

FDA Approved (Vyleesi)

PT-141

Bremelanotide (Vyleesi®)

1025.2 g/mol →

Phase 3 Clinical Trials

Retatrutide

LY3437943 (Eli Lilly)

~4300 g/mol →

Research peptide — approved in Russia; not FDA/EMA approved

Selank

Threonyl-Lysyl-Prolyl-Arginyl-Prolyl-Glycyl-Proline (tuftsin analog TP-7)

751.88 g/mol →

FDA/EMA Approved

Semaglutide

GLP-1 Receptor Agonist

4113.58 g/mol →

Research peptide — approved as a medicine only in Russia; not approved by the FDA or EMA

Semax

Semax (Met-Glu-His-Phe-Pro-Gly-Pro), a synthetic analog of ACTH(4-10)

813.92 g/mol →

Active Research

Sermorelin

Sermorelin Acetate (GHRH 1-29)

3357.9 g/mol →

Preclinical only: rodent and cell studies, no published human data, not approved by any regulator

SLU-PP-332

SLU-PP-332, a synthetic pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ)

290.32 g/mol →

Granted FDA accelerated approval in Barth syndrome (2025); under study in other indications

SS-31 (élamipretide)

D-arginyl-2',6'-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide (elamipretide, MTP-131, Bendavia)

639,80 g/mol →

Mazdutide approved in China only. Survodutide and cagrilintide remain investigational and are not approved in any country.

Survodutide, Mazdutide and Cagrilintide

Survodutide (BI 456906), mazdutide (IBI362 / LY3305677) and cagrilintide (AM833)

Survodutide: approximately 4231.7 g/mol →

Active research

TB-500

Thymosin Beta-4 Fragment

4963.50 g/mol →

FDA Approved (2010)

Tesamorelin

trans-3-hexenoyl-human growth hormone-releasing factor (1-44) amide

5135.86 g/mol →

Approved as a drug (thymalfasin/Zadaxin) in some countries; not FDA/EMA approved — investigational elsewhere

Thymosin Alpha-1

Thymosin Alpha-1 (Thymalfasin, Tα1)

3108.30 g/mol →